GlaxoSmithKline To Bid Over $15 Billion For Pfizer Inc. Unit

LONDON, June 2 (Reuters) - By Ben Hirschler, European Pharmaceuticals Correspondent-- GlaxoSmithKline Plc is to bid more than $15 billion for the consumer healthcare business of U.S. rival Pfizer Inc, people familiar with the situation said on Friday. The move raises the bar in the auction for the $3.88-billion-a-year over-the-counter (OTC) medicines unit, whose top-selling brands include Listerine mouthwash, Sudafed decongestant and Rolaids antacid.